Is the Weight Over? Next Generation of Anti-Obesity Therapeutics
Host: John Russell, MD
\n\n Guest: Robert F. Kushner, MD
\n\n\n \n
Obesity affects 600 million people globally and over one third of the American population. Along with associated comorbidities, including cardiovascular disease, stroke, diabetes, and cancer; the direct and indirect costs of managing obesity are 21% of the total medical costs. The elevated risk for severe disease and death from COVID-19 associated with obesity and its comorbidities underscores the urgency to develop and implement effective prevention and treatment strategies. Current strategies for treating obesity rely on a "one-size-fits-all" approach despite significant pathophysiological heterogeneity among people with obesity. As a result, the response to obesity pharmacotherapy as well as diet and lifestyle interventions continues to be a hit-or-miss phenomenon with highly variable efficacies and outcomes. Currently available drugs only offer a 5% weight loss (in comparison to placebo) if both drug and placebo are given with a lifestyle intervention. However, we are now seeing the emergence of second-generation medications. Knowledge of the safety and efficacy of newly available therapeutic options is vital to health care practitioners as they work with patients to develop optimal, individualized, and long-term strategies for overcoming obesity.